A Phase 2a, Randomized, Double-blind, Placebo-controlled, Two Period, Crossover Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs CK 2127107 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 02 Aug 2017 According to a Cytokinetics media release, the company expect Astellas to continue enrollment in this study in 2017.
- 23 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 23 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.